Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | LTA4H | P09960 | 6/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911292 | 0.88 | CA1 (0.53) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL910120 | 0.87 | CA1 (0.54) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL911142 | 0.84 | LTA4H (0.57) | CA12CA1CA2CA9LTA4H | |
| SCHEMBL911231 | 0.84 | LTA4H (0.55) | CA12CA1CA2CA9LTA4H | |
| SCHEMBL16572363 | 0.83 | CA12 (0.50) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL11932189 | 0.82 | LTA4H (0.52) | LTA4HKMT2A | |
| SCHEMBL16627553 | 0.81 | CA1 (0.53) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL16572342 | 0.80 | MAPT (0.53) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL23291248 | 0.80 | CA1 (0.51) | CA12CA1CA2CA9LTA4H | |
| SCHEMBL910742 | 0.80 | CA1 (0.55) | CA12CA1CA2CA9SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-1922073-B1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8211895-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211895-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7807834-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807834-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807834-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1922073-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007018640-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003832-A1 | NEW CAPPED Pyrazinoylguanidine SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | CA12 1452/4885CA1 1345/4885CA2 165/4885 |
| US-20120220606-A1 | NEW CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, HCN4 | CA12 1452/4885CA1 1345/4885CA2 165/4885 |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | CA12 1452/4885CA1 1345/4885CA2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.